Nanoparticle-based PDT Collaboration Focuses on Proof of Concept Studies
London, UK, 7 September 2006 - Cancer Research Technology Limited (CRT), the University of East Anglia, and the University of Padua have today released details of a collaboration focusing on proof of concept anti-cancer studies of an exciting nanoparticle-based photodynamic therapy (PDT).
The technology exploits a three-component system: metal nanoparticles, novel phthalocyanine photosensitisers and phase transfer reagent. The combination produces enhanced levels of cytotoxic singlet oxygen, resulting in increased cell kill following activation by red light. The wavelength of red light provides maximal tissue penetration and minimal risk to healthy tissues.
Combining phthalocyanines with gold nanoparticles improves solubility, thereby avoiding the requirement for liposomal formulation. The nanoparticle conjugate may also provide a systemic delivery vehicle for other photosensitisers limited by solubility. Importantly, phthalocyanine solubility has been improved without the inherent problems associated with the generation of isomers. In addition, the phthalocyanines are characterised by low absorption in both the UV and the visible wavelength range outside the “red” (>600 nm) interval, potentially reducing skin photosensitivity, one of the major hurdles of treatment with PDT.
Lead investigator, Prof. David Russell at the School of Chemical Sciences and Pharmacy, University of East Anglia will receive funding from Cancer Research UK and will work closely with Prof. Giulio Jori, a leading expert in PDT at the Department of Biology, University of Padua. CRT has exclusive rights to commercialise the strong patent portfolio and therapeutic opportunities arising from the programme. Revenues will be shared with the University of East Anglia and the University of Padua.
---ends---
For further information:
Cancer Research Technology Limited
Roisin NicAmhlaoibh, Business Manager +44 (0)207 269 3640
rnicamhlaoibh@cancertechnology.com
About Photodynamic Therapy
Photodynamic therapy (PDT) combines the use of a photoactive agent, termed a photosensitiser, with light to cause selective damage to target tissues. Light activation leads to the production of cytotoxic singlet oxygen. PDT is characterised by a series of advantages as compared with other therapeutic modalities for cancer including minimally invasive and targeted treatments, limited toxicities permitting repeat dosing and improved patient quality of life. Photosensitisers have received regulatory approval for the treatment of a series of cancers including: skin, lung, head and neck, gastric, bladder and cervical.
About the University of East Anglia
The University of East Anglia (UEA) is an internationally renowned, research-led University, known for its pioneering and collaborative approach to research which brings together academics from different disciplines to create innovative research groups. All of UEA’s research units within the Faculty of Science were rated as being internationally or nationally excellent in the last Government-sponsored Research Assessment Exercise in 2001. The University’s School of Chemical Sciences and Pharmacy cuts across traditional divides, integrating basic chemical research with the applied science of pharmacy. Further information about UEA can be found at www.uea.ac.uk.
About the University of Padua
The University of Padua is one of the most ancient Universities, having being founded in 1222. Since its beginning, the University promoted a large variety of curricula, as indicated by its initial Latin denomination “Gymnasium Omnium Disciplinarum”. In particular, it strongly promoted innovative research and carefully supported academic freedom, as shown by the prestigious scientists who taught in its lecture halls, including Galileo, Copernicus and William Harvey; important milestones in the history of the University of Padua are the foundation of the first botanical garden in 1545, the introduction of autopsies with the construction of the first permanent anatomy theatre in 1594, and the first historically documented example of a lady who obtained a University degree, namely Elena Lucrezia Cornaro in 1678. At present, the University is attended by about 55,000 students spread among 13 Faculties, offering 93 degree courses, as well as many Master’s courses. Most faculties were rated as being excellent for their quality in educational activities by a national assessment committee during the past 3 years. The Department of Biology includes about 70 full or associate professors and is noted for the interdisciplinary nature of the large majority of investigations carried out by its components, many of which through collaborations at an international level.
About Cancer Research Technology
Cancer Research Technology Limited (CRT) is an oncology-focused development and commercialisation company that realises cancer patient benefit from publicly- funded research worldwide. CRT works closely with leading international cancer scientists, their institutes and funding bodies to protect, develop and commercialise oncology-related discoveries. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found at www.CancerTechnology.com.
|
